Evidence map›Paper›PMID 24632529›Full record

ArticleNeuropharmacology2014

Sensitized nucleus accumbens dopamine terminal responses to methylphenidate and dopamine transporter releasers after intermittent-access self-administration.

Erin S Calipari, Sara R Jones

Abstract read
In one paragraph

Article in Neuropharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Effects of Methylphenidate on the Dopamine Transporter and Beyond.Current topics in behavioral neurosciences · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Modeling the development of drug addiction in male and female animals.Pharmacology, biochemistry, and behavior · 2018
    Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Erin S CalipariDepartment of Physiology and Pharmacology, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA.
Sara R JonesDepartment of Physiology and Pharmacology, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA. Electronic address: srjones@wakehealth.edu.
Wake Forest University · US

Funding

A Novel Animal Model of Cocaine AddictionR01DA014030 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI JONES, SARA RAULERSON · 2001 to 2015
$3.2M
NEUROSCIENCE OF DRUG ABUSE TRAINING PROGRAMT32DA007246 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CHILDERS, STEVEN R · 1991 to 2011
$2.2M
Dopamine Transporter Changes Following Cocaine Self-AdministrationR01DA021325 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI JONES, SARA RAULERSON · 2007 to 2011
$1.4M
Methylphenidate, Serotonin and Dopamine InteractionsR01DA030161 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI JONES, SARA RAULERSON · 2010 to 2014
$1.4M
The effect of methylphenidate use and abuse on dopamine system kineticsF31DA031533 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CALIPARI, ERIN · 2012 to 2013
$63k
NIDA NIH HHS F31 DA031533NIDA NIH HHS R01 DA014030NIDA NIH HHS R01 DA021325NIDA NIH HHS R01 DA030161NIDA NIH HHS T32 DA007246
6 · The paper itself

Abstract

Long-access methylphenidate (MPH) self-administration has been shown to produce enhanced amphetamine potency at the dopamine transporter and concomitant changes in reinforcing efficacy, suggesting that MPH abuse may change the dopamine system in a way that promotes future drug abuse. While long-access self-administration paradigms have translational validity for cocaine, it may not be as relevant a model of MPH abuse, as it has been suggested that people often take MPH intermittently. Although previous work outlined the neurochemical and behavioral consequences of long-access MPH self-administration, it was not clear whether intermittent access (6 h session; 5 min access/30 min) would result in similar changes. For cocaine, long-access self-administration resulted in tolerance to cocaine's effects on dopamine and behavior while intermittent-access resulted in sensitization. Here we assessed the neurochemical consequences of intermittent-access MPH self-administration on dopamine terminal function. We found increased maximal rates of uptake, increased stimulated release, and subsensitive D2-like autoreceptors. Consistent with previous work using extended-access MPH paradigms, the potencies of amphetamine and MPH, but not cocaine, were increased, demonstrating that unlike cocaine, MPH effects were not altered by the pattern of intake. Although the potency results suggest that MPH may share properties with releasers, dopamine release was increased following acute application of MPH, similar to cocaine, and in contrast to the release decreasing effects of amphetamine. Taken together, these data demonstrate that MPH exhibits properties of both blockers and releasers, and that the compensatory changes produced by MPH self-administration may increase the abuse liability of amphetamines, independent of the pattern of administration.

Indexed as

AmphetamineAnimalsCocaineDopamineDopamine Plasma Membrane Transport ProteinsDose-Response Relationship, DrugMaleMethylphenidateNucleus AccumbensRats, Sprague-DawleyReceptors, Dopamine D2Self AdministrationSubstance-Related DisordersTime FactorsAmphetamineCocaineDopamineDopamine Plasma Membrane Transport ProteinsMethylphenidateReceptors, Dopamine D2AmphetamineCocaineMethylphenidateRatSelf-administrationVoltammetry

Identifiers

PMID24632529
PMCPMC4028393
OpenAlexW2081242641

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.